2[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res,2004,64(19):7099
3[2]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial(RDT)of Sorafenib(Bay 43-9006)in patients with advanced renal cell carcinoma(RCC).J Clin Oncol,2005,23(16s)Abstr 4544
4[3]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of Sorafenib in advanced renal cell carcinoma (RCC):Impact of crossover on survival.J Clin Oncol,2006,24(18s):Abstr 4524
5[4]Ryan CW,Goldman BH,Lara PN,et al.Sorafenib plus interferon-α2b(IFN)as first-line therapy for advanced renal cell carcinoma(RCC):SWOG 0412.J Clin Oncol,2006.24(18s):Abstr 4525
6[5]Abou-Alfa GK,Schwartz L,Ricci S,et al.Phase Ⅱ study of sorafenib in patients with advanced hepatoeellular carcinoma.J Clin Oncol,2006,24(26):4293
7[6]Richly H,Henning BF,Kupsch P,et al.Results of a Phase I trial of sorafenib(BAY 43-9006)in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17(5):866
9[8]Lorigan P,Corrie P,Chao D,et al.Phase Ⅱ trail of sorafenib combined with dacarbazine in metastatic melanoma patients.J Clin Oncol,2006,24(18s):Abstr 8012
10[9]Flahertv KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin(C)and paclitaxel(P)demonstrates Dreliminary antitumor activity in the expansion chort of Datients with metastatic melanoma.J Clin Oncol,2004,23:Abstr 7507
1Llovet JM, Bru C, Bruix J. Prognosis of hepatocel- lularcarcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999,19(3):329-338.
2Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome[J]? Eur J Cancer, 2006, 42(4): 548-556.
3Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006[J]. J Clin Onco, 2006, 24(9):1363-1369.
4Azad N S, Aragon- Ching J B, Dahut W L, et al. Hand foot skinreactionincreases withcumulative sorafenib dose and withcombination anti - vascaular endothelial growth factor therapy[J]. Clin Cancer Res, 2009, 15." 1411.
5Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolera- bility in elderly patients with advanced renal cell carcino-ma :results from a large pooled analysis [J]. Br J Cancer, 2013,108(2) :311-318.
